Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,707 across all filing types
Latest filing 2021-09-02 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Book closure for the purpose of AGM and E-voting
Regulatory Filings
2021-09-02 English
Annual Report for the year 2020-21
Regulatory Filings
2021-09-02 English
Book Closure
AGM Information Classification · 95% confidence The document text contains information about book closure dates, cut-off dates for voting eligibility, and remote e-voting commencement and end times specifically related to the 39th Annual General Meeting (AGM). These details are typical of materials shared to inform shareholders about the AGM logistics rather than the AGM report itself. The document is short (496 characters) and focuses on procedural information for the AGM, which aligns with AGM Information filings rather than voting results or proxy materials. Therefore, the document is best classified as AGM Information (AGM-R).
2021-09-02 English
Natco Pharma (Canada) Inc. announces the launch of Pr NAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid®
Regulatory Filings
2021-09-02 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated September 2, 2021, from Natco Pharma Limited addressed to stock exchanges (BSE and NSE) disclosing information under SEBI (LODR) Regulations 2015. The content announces the launch of a new pharmaceutical product, PrNAT-LENALIDOMIDE Capsules, the first generic alternative to Revlimid, including details about the product, its indications, and market impact. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document is a corporate announcement about a product launch and does not fit into financial report categories such as Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not related to board changes, voting results, or legal proceedings. The document is a regulatory disclosure announcement to stock exchanges about a significant business development. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (6861 characters) and content support this classification with high confidence.
2021-09-02 English
Loss of Share Certificates
Regulatory Filings
2021-08-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.